Please select an option below to help us tailor your newsletter to best suit your content interests!
2020 Top Stories in Advanced Melanoma: Drastic Improvement in Melanoma Mortality With Novel Agents Written by Ari VanderWalde MD, MPH, FACP Despite a plethora of interesting findings and results of novel clinical trials in melanoma in 2020, I believe the most important story of the year was actually a small, easy-to-overlook, 3-page report in the American… Read more »
Axel Grothey, MD, medical oncologist and our Director of Gastrointestinal Cancer Research, discusses the role of precision medicine in colorectal cancer (CRC) with OncLive. Grothey says, “With the rise of molecular profiling, the field of CRC has shifted away from a one-size-fits-all approach and entered an era of precision medicine. Notably, molecular profiling guides the… Read more »
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane (Abstract GS4-01)…. Read more »
Ari VanderWalde, MD, MPH, Bioeth, West Cancer Center and Research Institute’s Director of Research, stands behind the safety and highly regulated protocols for participants in clinical trials. Dr. VanderWalde recognized the importance and urgency to create a safe and effective vaccine to combat COVID-19. “I had a 50% chance of getting the vaccine and 50%… Read more »
West physicians Dr. Ari VanderWalde, Dr. Axel Grothey, Dr. Daniel Vaena, Dr. Gregorgy Vidal, Dr. Adam ElNaggar, & Dr. Lee Schwartzberg recently published a study on the establishment of a Molecular Tumor Board & Uptake of Recommendations in a Community Setting. Abstract In the precision medicine era, molecular testing in advanced cancer is foundational… Read more »
Gregory Vidal, MD, PhD, West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in HER2-positive breast cancer. Gregory Vidal, MD, PhD, of West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in… Read more »
OneR and West Cancer Physicians Give Ten Presentations at SABCS OneOncology, the national network of independent oncology practices, announced today that physicians from OneR, the OneOncology Research Network and West Cancer and Research Institute will share results from ten research studies at the San Antonio Breast Cancer Symposium® (SABCS®), an international gathering of physicians and… Read more »
Axel Grothey, MD The New England Journal of Medicine (NEJM) has recently published an editorial entitled “Pembrolizumab as first-line therapy in mismatch repair-deficient advanced colorectal cancer: A new standard of care” written by West Cancer Center’s GI Medical Oncology Lead and GI Oncology Clinical Research Director, Dr. Axel Grothey. Click the link below… Read more »
Matching patient populations with a targetable genomic alteration to a specific investigational study is the aim of a new clinical trial through OneR and Genentech. This partnership will facilitate collaborations on various clinical trials, scientific research and real-world data studies that will advance personalized cancer care at community oncology centers like West. “With too many… Read more »
West Clinic Offers Patients Even More Oncology Treatment Options West joins launch of new technology platform, OneR, to increase trial therapies for patients As an affiliate of OneOncology, West Clinic now has the ability to further its clinical trial offerings and oncology research knowledge by joining the launch of OneR. OneR is a… Read more »